Search

Daniel Scoles

from Sandy, UT
Get Report
Connected to:
Ann M Scoles, 32April C Scoles, 68Bob L Scoles, 76Cody A Scoles, 53Daniel R Scoles, 62Drew H Scoles, 38Jack Scoles, 34Nathaniel Scoles, 43Paul Scoles, 74Randy A Scoles, 63

Daniel Scoles Phones & Addresses

  • Sandy, UT

Publications

Us Patents

Staufen1 Regulating Agents And Associated Methods

View page
US Patent:
20210238590, Aug 5, 2021
Filed:
Jun 14, 2019
Appl. No.:
15/734174
Inventors:
- Salt Lake City UT, US
Daniel R. Scoles - Salt Lake City UT, US
Sharan Paul - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
C12N 15/113
A61K 45/06
Abstract:
Methods of minimizing dysregulation of Staufen1-associated RNA metabolism can include introducing an amount of a Staufen1-regulating agent to a target cell sufficient to minimize the dysregulation. Therapeutic compositions for treating a neurodegenerative condition associated with Staufen1-induced dysregulation of RNA metabolism can include a therapeutically effective amount of a Staufen1-regulating agent and a pharmaceutically acceptable carrier.

Staufen1 Agents And Associated Methods

View page
US Patent:
20200069721, Mar 5, 2020
Filed:
Dec 8, 2017
Appl. No.:
16/467945
Inventors:
- Salt Lake City UT, US
Daniel R. Scoles - Salt Lake City UT, US
Sharan Paul - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
A61K 31/713
A61K 45/06
A61P 25/28
C12N 15/113
Abstract:
Methods of minimizing dysregulation of Staufen1-associated RNA metabolism can include introducing an amount of a Staufen1 -regulating agent to a target cell sufficient to minimize the dysregulation. Therapeutic compositions for treating a neurodegenerative condition associated with Staufen1-induced dysregulation of RNA metabolism can include a therapeutically effective amount of a Staufen1-regulating agent and a pharmaceutically acceptable carrier.

Methods For Modulating Ataxin 2 Expression

View page
US Patent:
20190017047, Jan 17, 2019
Filed:
May 7, 2018
Appl. No.:
15/973088
Inventors:
- Carlsbad CA, US
- Salt Lake City UT, US
Stefan M. Pulst - Salt Lake City UT, US
Daniel R. Scoles - Salt Lake City UT, US
Gene Hung - San Diego CA, US
Assignee:
Ionis Pharmaceuticals, Inc. - Carlsbad CA
University of Utah Research Foundation - Salt Lake City UT
International Classification:
C12N 15/113
Abstract:
Disclosed herein are methods for decreasing Ataxin 2 mRNA and protein expression. Such methods are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism.

Methods For Modulating Ataxin 2 Expression

View page
US Patent:
20170175113, Jun 22, 2017
Filed:
Mar 19, 2015
Appl. No.:
15/127352
Inventors:
- Carlsbad CA, US
- Salt Lake City CT, US
Stefan M. Pulst - Salt Lake City UT, US
Daniel R. Scoles - Salt Lake City UT, US
Gene Hung - San Diego CA, US
Assignee:
Ionis Pharmaceuticals, Inc. - Carlsbad CA
University of Utah Research Foundation - Salt Lake City UT
International Classification:
C12N 15/113
Abstract:
Disclosed herein are methods for decreasing Ataxin 2 mRNA and protein expression. Such methods are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism. Provided are methods for reducing expression of Ataxin 2 (ATXN2) mRNA and protein in an animal. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases, including spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism by inhibiting expression of Ataxin 2 in an animal.
Control profile
Daniel Scoles from Sandy, UT Get Report